Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed an agreement with Otto-von-Guericke University Magdeburg to conduct a study evaluating iclaprim in an in vitro model of ocular toxoplasmosis. The research will focus on toxoplasma chorioretinitis, an orphan disease that is a type of ocular toxoplasmosis, a parasitic disease that may result in severe life-threatening infections and/or blindness. The work will be led by Prof. Dr. Ildiko Rita Dunay, Director, Institute of Inflammation and Neurodegeneration at the university.
Dr. David Huang, Chief Medical Officer of Motif Bio, said: “We are very pleased to work with Dr. Dunay, who is an expert in the area of toxoplasmosis. In vitro data indicate that iclaprim has activity against toxoplasma. The data generated from Dr. Dunay’s lab will be important in understanding whether iclaprim can play a role in this potentially devastating, progressive and recurring necrotizing retinitis, including vision-threatening complications.”